Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "United States PENTHROX Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about PENTHROX for acute pain in the United States.
A detailed picture of the PENTHROX for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the PENTHROX for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
Further, it also consists of future market assessments inclusive of the PENTHROX market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.
Drug Summary
PENTHROX (methoxyflurane) is a fast onset, inhaled, non-opioid analgesic intended for the emergency treatment of pain. It induces muscle relaxation and reduces pain sensitivity by modulating tissue excitability. It does this by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
PENTHROX Analytical Perspective
In-depth PENTHROX Market Assessment
This report provides a detailed market assessment of PENTHROX for acute pain in the United States. This segment of the report provides forecasted sales data from 2026 to 2032.
PENTHROX Clinical Assessment
The report provides the clinical trials information of PENTHROX for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PENTHROX dominance.
- Other emerging products for acute pain are expected to give tough market competition to PENTHROX and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PENTHROX in acute pain.
- Our in-depth analysis of the forecasted sales data of PENTHROX from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PENTHROX in acute pain.
Key Topics Covered:
1. Report Introduction
2. PENTHROX Overview in Acute pain
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. PENTHROX Market Assessment
5.1. Market Outlook of PENTHROX in Acute pain
5.2. The United States Analysis
5.2.1. Market Size of PENTHROX in the United States for Acute pain
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2psgnw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
